The cdk2 gene has been identi®ed as a human cdc2/ CDC28-related gene that encodes a protein kinase essential for the G1/S transition in mammalian cells, but not for the G2/M transition, which requires Cdk1, another p34 cdc2/CDC28 homolog. Novel potential functions of Cdk2 have been uncovered by using two potent and speci®c inhibitors of its kinase activity, roscovitine and olomoucine, on human wt p53-expresser untransformed and tumor-derived cells. At concentrations equal or superior to respectively 30-and 20-fold their in vitro IC 50 values for cyclin B/Cdk1, cyclin A/Cdk2 and cyclin E/Cdk2, the Cdk inhibitors precipitately induce a dramatic nuclear accumulation of wt p53 and a delocalization of nucleolin from the nucleolus in all interphase cells, whatever their cell cycle status, acting in this way like the DNA-damaging drug, mitomycin C (7 mg/ml). These early events are soon followed by a nucleolar fragmentation in both normal and tumor cells in the presence of the Cdk inhibitors but not in the presence of the DNA-damaging drug. Yet, treatment with either type of compounds eventually triggers rapidly the death of the tumor cells and, much more slowly, that of the normal cells. The Cdk inhibitors, however, stimulate cell death from any stage of the cell cycle, whereas the DNA-damaging drug kills more ecaciously S phase cells. These observations provide a hint that the Cdk2 kinase might be involved in controlling the nuclear levels of the tumor suppressor wt p53 protein and in maintaining the nucleolar integrity and function, linking in this way the cell division cycle machinery to survival functions and overall cell metabolism via the control of nucleocytoplasmic transport and of ribosome production.
Introduction
In yeast, a single protein kinase appears to be essential for the initiation of both S and M phases. It is the CDC28 gene product in Saccharomyces cerevisiae and the cdc2 + gene product in Schizosaccharomyces pombe (Forsburg and Nurse, 1991, for review). The two proteins are highly related structurally and functionally and encode a serine/threonine protein kinase that is homologous to the 34 kDa protein kinase of vertebrate and invertebrate MPF (M phase Promoting Factor; Meijer et al., 1995 Meijer et al., , 1996 Meijer et al., , 1997a , for review). The situation is dierent in higher eukaryotes in which distinct, yet structurally similar kinases, are required to execute G1 functions and the G1/S transit and to trigger the onset of mitosis which still relies on the activation of a p34 cdc2/CDC28 homolog (called Cdk1) complexed with a regulatory B-type cyclin (Lees, 1995, for review) .
A family of human Cdc2-related protein kinases has been identi®ed (Meyerson et al., 1992) , four of which at least (Cdk2, Cdk3, Cdk4 and Cdk6) are involved in regulating the route in G1 phase and the G1-to-S crossing (Xiong et al., 1992; Matsushime et al., 1992; Meyerson and Harlow, 1994; Ko et al., 1992; Dulic et al., 1992; Tsai et al., 1991 Tsai et al., , 1993 Bates et al., 1994) . The best studied of these kinases is Cdk2, which is capable of complementing cdc2/CKC28 mutations in yeasts and is a homolog of Xenopus Eg1 (Paris et al., 1991; Elledge and Spottswood, 1991; Ninomoya et al., 1991) . The Cdk2 protein level is low, yet readily detectable, in quiescent human ®broblasts; it rises continuously after serum re-stimulation and then remains constant in cycling cells. Its in vitro kinase activity emerges visibly in late G1 phase, well before the Cdk1 activity and is the highest in S phase and G2 cells (Pagano et al., 1993; Tsai et al., 1993) . The activation of cyclin E/Cdk2 complexes has been shown to contribute for the major part to the early-appearing Cdk2 activity (Dulic et al., 1992; Ko et al., 1992; Pagano et al., 1993; Tsai et al., 1993) and that of cyclin A/Cdk2 complexes accounts for almost all of the S and G2 phase activities (Tsai et al., 1991; Elledge et al., 1992; Rosenblatt et al., 1992; Pagano et al., 1993; Tsai et al., 1993) . D-type cyclins as well, which are induced very soon after mitogen stimulation, may be able to form quaternary complexes with Cdk2, p21 and repair factor PCNA (Xiong et al., 1992) . In addition to its assembly with speci®c cyclin subunits, the full activation of Cdk2 requires phosphorylation of T160 (by the CDK-activating kinase, CAK; Lees, 1995, for review) which increases its electrophoretic mobility on polyacrylamide gels. Partial activation of Cdk2, however, can be achieved in vitro after cyclin A binding alone and independently of CAK (ConnellCrowley et al., 1993) . Inhibitory phosphorylations of Cdk2 occur on Y15 and, to a lesser extent, on T14 without aecting its apparent molecular weight .
A variety of experimental approaches have been used to gain an insight into the in vivo functions of the Cdk2 kinase. Thus, microinjections of anti-cyclin A or anti-Cdk2 antibodies or of antisense cyclin A cDNA plasmid, like tranfection of a dominant negative Cdk2, prevent the onset of DNA replication (Girard et al., 1991; Pagano et al., 1992 Pagano et al., , 1993 Zindy et al., 1992; Tsai et al., 1993; Van den Heuvel and Harlow, 1993) . Depletion of the Xenopus Cdk2 homolog, but not of Cdk1, from activated egg extracts blocks DNA synthesis (Fang and Newport, 1991) . All these data support the notion that the Cdk2 kinase activity is indispensable for the G1/S transition. In addition, overexpression of cyclin E in dierent cellular backgrounds has uncovered another role for the cyclin E/ Cdk2 complexes, shared with cyclin D1/Cdks complexes and c-Myc, which is to control the duration of G1 phase and cell size (Ohtsubo and Roberts, 1993; Jiang et al., 1993; Quelle et al., 1993; Resnitzky et al., 1994; Wimmel et al., 1994; Musgrove et al., 1994; Resnitzky and Reed, 1995; Karn et al., 1989) .
Each technique, however, has limits. For instance, when microinjection experiments with antibodies directed against either cyclin A or cyclin E or Cdk2 are performed, it can never be excluded that the antibodies could bind speci®cally to their antigen without in¯uencing its association with its in vivo substrates or its activity. Alternatively, the antibodies may fail to interact with a particular subset of antigens because they are located at inaccessible sites, or because the epitope is masked in vivo by an unknown protein-protein interaction. Another complementary way to address the question of the in vivo functions of the active Cdk2 complexes is by using speci®c inhibitors. Such compounds have been recently actively searched for after it had been realized that tumor cells frequently exhibit deregulated Cdks and, in addition, aberrantly express their regulatory cyclin subunits, raising the possibility that chemical Cdk inhibitors could be potentially ecacious in cancer therapy (Meijer, 1996, for review) . Two purines have been demonstrated so far to display a narrow speci®city towards Cdk1, Cdk2, Cdk5, among 35 kinases tested: olomoucine, the IC 50 value for cyclin B/Cdk1, cyclin A/ Cdk2, cyclin E/Cdk2 and brain-speci®c p35/Cdk5 is of the order of 7 mM (Vesely et al., 1994) and roscovitine, the IC 50 values for cyclin B/Cdk1, cyclin A/Cdk2, cyclin E/Cdk2 and p35/Cdk5 are respectively 0.65, 0.7, 0.7 and 0.16 mM (Meijer et al., 1997b; De Azevedo et al., 1997) . The two Cdk inhibitors have already been tested on a variety of biological systems (Meijer and Kim, 1997, for review) . Both reduce the growth rate of many mammalian cells (Schutte et al., 1997) . Olomoucine stimulates massive apoptosis in cells arrested in G2 with DNA-damaging agents (Ongkeko et al., 1995) and, yet, it displays an anti-apoptotic activity in postmitotic neuronally dierentiated PC12 cells and in sympathetic neurons (Park et al., 1996) . Roscovitine, on the other hand, (i) reversibly arrests star®sh oocytes and sea urchin embryos in late prophase, (ii) inhibits in vitro MPF activity and in vitro DNA synthesis in Xenopus egg extracts, (iii) blocks progesterone-induced maturation of Xenopus oocytes and in vivo phosphorylation of the elongation factor eEF-1 and of vimentin, (iv) triggers the death of human Jurkat T cells.
We previously reported that the nuclear accumulation of wt p53 during a normal cell division cycle in human wt p53-expresser untransformed and tumor cells is unrestricted in G1 phase but is restrained and eventually stops after the G1/S transition. More recently, we found that the treatment with some DNA-damaging agents (like 7 mg/ ml mitomycin C) of the two types of cells quickly induces a dramatic nuclear accumulation of wt p53 in all cells independently of their cell cycle status. This eventually leads to a stable G1 arrest in normal cells, but, a rapid killing of S phase cells in the tumor cell line. Remarkably, the G1-arrested normal cells coexpress in their nucleus very high levels of both wt p53 and p21 WAF1/CIP1/SDI1 whereas the tumor cells die at the onset of or in S phase with elevated nuclear levels of wt p53 but almost none of p21 (unpublished results). Tumor cells in general lack a strict restriction point control (Pardee, 1974 (Pardee, , 1989 which may result in part from their incapability at inactivating the G1 cyclin/ Cdk2 via the formation of stable complexes with p21 WAF1/CIP1/SDI1 and PCNA (Xiong et al., 1993a) . We speculated then that the MCF-7 cells could possibly be protected from death in S phase following DNA damage if their G1-to-S transit was prevented by direct inhibition of the activity of a G1 cyclin/Cdk involved in controlling entry in S phase. This idea was tested using roscovitine and olomoucine to try protecting from death G1-synchronized MCF-7 cells treated with mitomycin C.
Unexpectedly, however, we found that the treatment of MCF-7 cells with roscovitine or olomoucine at concentrations equal or superior to respectively 30-and 20-fold their in vitro Cdk IC 50 values (at which the in vitro-measured complex activities do not exceed background levels) was as toxic as the treatment with mitomycin C, killing half of the cell populations from any cell cycle stage by 24 h. Intriguingly also, the Cdk inhibitors, like mitomycin C, very rapidly induced a strong nuclear accumulation of wt p53 and a delocalization of nucleoline from the nucleolus in both human untransformed and tumor cells, independently of their cell cycle status. These early events were followed by an almost complete fragmentation of the nucleoli in the presence of the Cdk inhibitors but not in the presence of the DNA-damaging agent. These unforeseeable results shed light on the possibility that a cyclin-dependent kinase activity might be devoted not only to the regulation of progression through the cell cycle but also to the control of generalized functions such as nucleocytoplasmic transport and ribosome production.
Results
Roscovitine induces nuclear accumulation of wt p53 and cell death in tumor-derived MCF-7 cells
In asynchronous MCF-7 cell populations, the highest nuclear concentrations of wt p53 protein are generally found in G1/early S phase cells . Yet, a strong wt p53 nuclear stockpiling in G1 as well as in S phase cells can readily be stimulated after exposure to DNA-damaging agents, quickly followed by the triggering of cell death (unpublished results).
Intriguingly, the treatment of these cells with 25 mM roscovitine (at which concentration the in vitromeasured Cdk complex activities do not exceed wt p53 nuclear induction by inhibition of Cdk2 kinase T David-Pfeuty et al background levels) induced cell death even more rapidly than 7 mg/ml mitomycin C at early times, although more slowly at later times (Figure 1 ). Because the morphology of the ®rst dying cells generated by either treatment appeared quite similar under the microscope, we thought of investigating the possibility that roscovitine could also force wt p53 to accumulate in the nucleus of treated cells, independently of their cell cycle status. Indeed, double immunolabeling experiments with anti-p53 and anti-cyclin A antibodies clearly demonstrated that the roscovitine treatment results in a dramatic nuclear accumulation of wt p53 in cyclin A-negative, G1 cells as well as in cyclin Apositive, S phase and G2 cells (Figure 2, upper panel) .
A few mitotic cells with a low level of wt p53 expression still survive after 16 h of treatment (at which time the cell viability has dropped down to *70%). These observations rule out the possibility that the MCF-7 cells would die especially from the mitotic stage and strongly suggest that the roscovitine eects on wt p53 nuclear accumulation and cell death are principally mediated via the inhibition of the Cdk2 kinase activity associated with either the cyclin E/Cdk2 or the cyclin A/Cdk2 complex or both.
In asynchronous populations, wt p53 is detected in the nucleus of a minority of cells, in contrast to the Cdk2 kinase which is substantially present in all interphase cell nuclei, although at a somewhat lesser extent in the postmitotic than in S phase and G2 cells (Figure 2 , lower panel). A few hours after the addition of roscovitine, practically all nuclei co-express the two proteins, albeit in variable proportions from one cell to Figure 2 Triple labeling of asynchronous MCF-7 cells treated with 25 mM roscovitine (Rosco 25) for the time indicated or not (C) with mAb anti-p53, anti-cyclin A (upper panel) or anti-Cdk2 (lower panel) and dapi and phase contrast image (C Ph). The arrows point to nucleolar area that appear as large, rounded and dark spots inside the nucleus and from which are excluded all immunolabelings (short and thin arrows). The long and thin arrows mark out nuclear area in morphologically aberrant cells in which concentrate the anti-p53 and anti-Cdk2 antibodies but not the DAPI staining. The larger arrows point to a morphologically aberrant cell with an unevenly spread DAPI staining The cell viability plots shown in Figure 1 are representative of asynchronous as well as of G1-synchronized MCF-7 cells. The rate of cell death was reproducibly constant in the presence of roscovitine whereas, in the presence of mitomycin C, it abruptly increased after an initial latency period which almost precisely corresponds to the time required for early G1 cells to enter S phase. The lag disappears if the cells are synchronized in early S phase with aphidicolin (4 mg/ ml, 16 h) before adding mitomycin C and *60% cell death occurs in 15 h under these conditions (instead of *40% for G1-synchronized cells). On the other hand, the cell viability plot of S phase synchronized MCF-7 cells treated with roscovitine remains linear although the cells die much faster than from G1 phase (*60 vs *40%, by 24 h).
Roscovitine induces delocalization of nucleolin from the nucleolus and nucleolar fragmentation in tumor-derived MCF-7 cells
In untreated MCF-7 cells, the speci®c antibodies directed against the wt p53, cyclin A and Cdk2 antigens decorate more or less intensely the whole nucleus with the exclusion of the nucleolar area, a few rounded and dark nuclear spots as seen in phase contrast (Figure 2, short and thin arrows). Strikingly, the immunolabeling patterns look more homogenous after the roscovitine treatment at the same time as the appearance of the nucleoli moves into numerous darker and smaller nuclear spots (Figure 2 , compare the phase contrast images in the`C' and`Rosco 25, 16 h' rows; see also the magni®ed ®eld in Figure 3) .
In untreated cells, the anti-nucleolin antibodies ( Figure 4 ) concentrate mostly in the nucleolar area identi®ed by phase contrast microscopy (short and thin arrows in the`C' row), although some antibody staining spreads through the nucleoplasm. The nuclear induction of wt p53 is already maximal by 4 h after the addition of 25 mM roscovitine, at which time the wt p53 staining is still excluded from the nucleolar area. Yet, the concentration of anti-nucleolin antibodies in these areas has drastically decreased whereas that spreading throughout the nucleoplasm is still signi®cant in most cells. After 16 h of treatment, almost all nucleoli have disintegrated into numerous fuzzy, small and dark nucleolin-free bodies (see also the magni®ed ®eld in Figure 3 ) and even the dispersed nuclear anti-nucleolin staining has disappeared from a number of cell nuclei, among which are the abnormally-condensed ones (arrowheads).
Neither a loss of nucleolin from the nucleoli, nor a nucleolar fragmentation, nor wt p53 nuclear accumulation occurred notably up to 10 mM roscovitine (at which concentration the Cdk complexes still exhibit a residual in vitro activity). Furthermore, olomoucine (which is tenfold less ecient than roscovitine at inhibiting Cdks in vitro) was able to generate the complete set of eects observed with 25 mM roscovitine, at concentrations above 150 mM. Consistently, 50 mM olomoucine was as ineective as 10 mM roscovitine. The isomer of olomoucine, isoolomoucine, which is quasi-inactive towards the Cdk complexes in vitro was also inecient in vivo, failing to generate the least particular phenotype at 500 mM. Another purine, purvalanol B, the IC 50 values for cyclin B/Cdk1, cyclin A/Cdk2, cyclin E/Cdk2 are respectively 6, 6, and 9 nM (Gray et al., 1998) also exerted the same eects as roscovitine in vivo, but, only starting from 5 mM, i.e. at a much higher concentration than expected considering its strong potency on the puri®ed enzymes. This could be due to a lesser permeability or a faster metabolization in cells of this particular compound. Interestingly, the exposure of the MCF-7 cells to 25 mM roscovitine or to 7 mg/ml mitomycin C induces very similar eects with respect to the nuclear accumulation of wt p53 and cell death. Yet, mitomycin C fails to induce an evident nucleolar fragmentation, although nucleolin still delocalizes from the nucleoli (Figure 4 ,`Mito 7, 16-h' row).
Figure 4 Double immunolabeling of asynchronous MCF-7 cells, treated as indicated on the left side of the ®gure, with mAb antip53 and anti-nucleolin and phase contrast image (C Ph). The short and thin arrows point to nucleolar area. Four hours treatment with 25 mM roscovitine is sucient to almost totally delocalize nucleolin from the nucleoli, although the nucleoli still do not appear highly disorganized in the phase contrast picture. By 16 h, the nucleoli have fragmented in a multitude of fuzzy, small and dark nucleolin-free bodies, only a fraction of which appear distinctly in the focal plan exposed. Treatment with 7 mg/ml mitomycin C induces a strong nuclear accumulation of wt p53, a delocalization of nucleolin from the nucleolus (already evident by 4 h); yet, the overall nucleolar architecture of the surviving cells look apparently unaltered. Ten mM roscovitine does not induce notably any of the phenotypes generated by 25 mM roscovitine. The arrowheads designate a dying cell showing a total loss of anti-nucleolin, but not of anti-p53, immunostaining wt p53 nuclear induction by inhibition of Cdk2 kinase T David-Pfeuty et al Dierential eects of roscovitine (10 and 25 mM) and mitomycin C (7 mg/ml) on G1 phase progression in MCF-7 cells Double immunolabeling with anti-p53 and anti-cyclin E antibodies of G1-synchronized MCF-7 cells and¯ow cytometry analysis (Figures 5 and 6, respectively) Cyclin E has been described as a nuclear G1-speci®c cyclin that reaches a maximal level of expression at the G1/S transition in a number of cultured cells (Ohtsubo et al., 1995) . The nuclei of most G1-synchronized MCF-7 cells (4 h after release from a nocodazole block) are still devoid of anti-cyclin E immunostaining whereas they already exhibit high levels of wt p53 (`C (NocR4 h)' row). The G1/S/G2-M distribution reaches then 77/10/9. 14 h later, a wave of entry in S phase has occurred in untreated cell populations (G1/S/G2-M*55/40/4) and the ratio of nuclear cyclin E-positive cells has risen above 50%. Conversely, that of nuclear wt p53-positive cells has drastically dropped or, in cells in which it is present, the wt p53 immunolabeling is generally less intense than at earlier times (`14 h (7)/C' row).
The addition of 10 mM roscovitine to G1-synchronized MCF-7 cells slows down the rate of entry in S phase (*22% after 14 h) and does not prevent the nuclear induction of cyclin E (`14 h (7)/C' row). It also reduces the rate of DNA replication since, by 24 h, the G1/S/G2-M distribution reaches 57/31/8 (against 46/40/12 in controls), and most of the S Figure 5 Double immunolabeling of G1-synchronized MCF-7 cells, treated or not for 14 h as indicated on the left side of the ®gure, with mAb anti-p53 and anti-cyclin E antibodies and phase contrast image (C Ph). Untreated (7); 10 and 25 mM roscovitine (Ro10) and (Ro25); 7 mg/ml mitomycin C (Mi7). Control cells (C) are MCF-7 cells released for 4 h from a nocodazole block (0.05 mg/ml for 18 h). This picture depicts the fact that G1-synchronized MCF-7 cells accumulate very little cyclin E in the presence of 25 mM roscovitine, but almost normal levels in the presence of 7 mg/ml mitomycin C or of 10 mM roscovitine wt p53 nuclear induction by inhibition of Cdk2 kinase T David-Pfeuty et al phase cells reside in the ®rst half of S phase (arrow in the`24 h (Ro10)/C' plot, Figure 6 ). Noticeably, cells that progress through G1 in the presence of 10 mM roscovitine lose their nuclear expression of wt p53 at least as rapidly as control cells that spend a shorter time in G1. Adding 25 mM roscovitine, instead of 10 mM, to G1-synchronized MCF-7 cells does not only prohibit almost completely S phase entry (G1/S/G2-M*79/10/ 7) but, it has totally opposing eects on the nuclear patterns of wt p53 and cyclin E expression: after 14 h, the nuclear level of wt p53 has dramatically raised in practically all cells which appear almost completely devoid of nuclear cyclin E (`14 h (Ro25)/C' row). Interestingly, in the presence of 7 mg/ml mitomycin C, the nuclear appearance of cyclin E is not prevented (`14 h (Mi7)/C' row) although the cells fail to enter S phase (G1/S/G2-M*80/10/5).
Western blot analysis (Figure 7) The preceding immuno¯uorescence data are fully corroborated by immunoblotting experiments showing that: (i) the wt p53 levels of expression are 6 ± 10-fold higher in G1-synchronized MCF-7 cells treated with either 25 mM roscovitine or 7 mg/ml mitomycin C than in control cells or in cells exposed to 10 mM roscovitine, after 12 h, and (ii) cyclin E readily accumulates in G1 cells exposed to either 10 mM roscovitine or 7 mg/ml mitomycin C but, barely, in G1 cells exposed to 25 mM roscovitine. Western blot analysis (like the immuno¯uorescence observations; not shown) also indicated that G1-synchronized MCF-7 cells treated with 25 mM roscovitine die before ever expressing signi®cant amounts of cyclin A. When exposed to 7 mg/ml mitomycin C, in contrast, they appear to enter S phase normally since cyclin A-positive cells emerge after 12 ± 14 h before disappearing later on. At last, immunoblots with anti-Cdk2 antibodies showed that the faster migrating and active form of Cdk2 rapidly accumulates in the presence or absence of 10 mM roscovitine but, not of 25 mM roscovitine. In the presence of 7 mg/ml mitomycin C, the faster Cdk2 component ®rst emerges and then disappears as the cell viability decreases. ) for 24 h in the presence of 10 mM (Ro10) or 25 mM roscovitine (Ro25), in the presence of 7 mg/ml mitomycin C (Mi7) or nothing (7). The X-axis and Y-axis indicate the relative propidium iodide¯uorescence (proportional to the DNA content) and the number of events (i.e., the cell #), respectively wt p53 nuclear induction by inhibition of Cdk2 kinase T David-Pfeuty et al respect to the cell cycle regulation of wt p53 nuclear expression: under standard growth conditions, the maximal levels of wt p53 are found in the nucleus of G1/early S phase cells, yet, a strong wt p53 nuclear accumulation in G1 as well as in S phase cells can be readily stimulated after exposure to DNA-damaging agents unpublished results) . Here we show that the treatment of asynchronous IMR-90 cells with 25 mM roscovitine (or 150 mM olomoucine) generate exactly the same initial eects as those depicted above in MCF-7 cells, i.e., (i) a rapid nuclear induction of wt p53 in cyclin A-negative, G1 cells as well as in cyclin A-positive, S phase and G2 cells (upper panel) and (ii) as a rapid delocalization of nucleolin from the nucleolus, associated with a nucleolar destructuration (lower panel) that do not occur as extensively up to 10 mM roscovitine or 50 mM olomoucine (`Rosco 10, 24 h' row). Similarly also in the two cell types, exposure to 7 mg/ml mitomycin C does not appear to induce a nucleolar fragmentation although it results into a delocalization of nucleolin from the nucleolus (not shown). However, the late response of the two cell types to the treatment with 25 mM roscovitine, as to the treatment with 7 mg/ml mitomycin, strongly diers since, the tumor-derived cells lose viability de®nitely much faster than the normal cells (Figure 1 ). Yet, the normal cells eventually die and cell loss amounts to 30% by 48 h, and to 50%, by 72 h.
Flow cytometry and Western blot analysis (Figures 6 and 7, respectively).
The immunoblotting experiments performed on G0/G1-synchronized IMR-90 cells (after release from 72-h serum starvation) gave the following information: (i) the wt p53 levels of expression are more than tenfold higher in G0/G1-synchronized IMR-90 cells treated for 24 h with either 25 mM roscovitine or 7 mg/ml mitomycin C (which remain arrested in G1 phase with a ratio of S phase cells that does not exceed 5%) than in cells exposed to 10 mM roscovitine for the same time period or in control cells (in which the G1/S/G2-M distributions reach 78/11/9 and 68/21/10, respectively); (ii) cyclin E is barely detectable in G0/G1-arrested IMR-90 cells and its level remains low in cells re-fed with 15% serum in the presence of 25 mM roscovitine; yet, it steadily and signi®cantly accumulates following release from the G0/G1 block in the absence or in the presence of 10 mM roscovitine or of 7 mg/ml of mitomycin C; (iii) the cyclin A patterns evolve in the same way as the cyclin E ones (with a time delay), except that a cyclin A induction is hardly detected after re-feeding with 15% serum in the presence of 7 mg/ml mitomycin C; (iv) the intensity of the faster migrating Cdk2 band is much weaker than the intensity of the slower migrating one in G0/G1-arrested IMR-90 cells; following re-entry in the cell cycle in the presence or absence of 10 mM of roscovitine, both Cdk2 components increase in concentration; in the presence of 25 mM roscovitine, both components emerge ®rst normally and decrease afterwards; in the presence of 7 mg/ml mitomycin C, both Cdk2 components accumulate, although somewhat slower than in control cells or in cells exposed to 10 mM roscovitine.
Discussion
Disruption of the cell cycle-dependent regulation of wt p53 nuclear expression by DNA damage and inhibitors of cyclin-dependent kinase 2 We reported earlier that the level of nuclear accumulation of wt p53 in human wt p53-expresser untransformed and tumor-derived cells is cell cycleregulated (David-Pfeuty et al., 1996; this study). More recently, we found that the tumor-derived MCF-7 cells treated with some DNA-damaging agents (like 7 mg/ml mitomycin) are prone to die selectively as they enter or during S phase. Extending these results, we show here that the treatment of MCF-7 cells with concentrations of the Cdk inhibitors, olomoucine and roscovitine, equal or superior to respectively 20-and 30-fold, their in vitro-measured IC 50 values for Cdks, triggers cell death even more rapidly than 7 mg/ml mitomycin at early times. Like mitomycin C, the Cdk inhibitors induce a dramatic stockpiling of wt p53 in the nucleus of all cells, irrespective of their position in the cell cycle and in normal cells as well. Yet, they stimulate the death of tumor cells in any phase of the cell cycle, albeit somewhat more quickly in S and G2 phases. Both types of agents eventually also kill normal cells but more slowly than tumor cells. G1-synchronized MCF-7 cells are killed before expressing to any signi®cant amount of cyclin E or of the faster migrating active Cdk2 form , suggesting that stable accumulation of the cyclin E/ Cdk2 complex depends on its activation. There is a previous report that 30 mM roscotine induces apoptosis in human Jurkat T cells . Since Jurkat T cells express a mutant p53, it has been inferred that roscovitine-induced apoptosis is p53-independent. Our own ®ndings would indicate that Cdk inhibitors acting like roscovitine are able to trigger apoptosis from S phase via a p53-dependent pathway, much like some DNA-damaging agents, as well as from other cell cycle phases, likely via p53-independent pathways. This hypothesis is supported by the observation that the human osteosarcoma Saos-2 cells (which exhibit extensive loss of p53-coding sequence) die signi®cantly less fast that the MCF-7 cells in the presence of 25 mM roscovitine and at a similar rate whether they are treated in G1 or S phase (*40% by 48 h; not shown).
DNA damage and inhibitors of cyclin-dependent kinase 2 induce delocalization of nucleolin from the nucleolus but only inhibitors of cyclin-dependent kinase 2 provoke nucleolar fragmentation
The nucleolus is a dense and highly refractile nuclear organelle which is the site of transcription of rDNA, of processing of the pre-rRNA transcripts, and of . Five hours treatment with 25 mM roscovitine is sucient to induce a strong wt p53 nuclear accumulation in all cells, whether they stain positively for cyclin A or not, as well as to delocalize nucleolin from the nucleoli (tiny arrowheads). The short and thin arrows in`C' point to a nucleolar area in which concentrates nucleolin. Following treatment for 24 h with 10 mM roscovitine, the nucleoli appear to have partially disaggregated (according to phase contrast microscopy), although nucleolin is still concentrated in them (short and thin arrows) wt p53 nuclear induction by inhibition of Cdk2 kinase T David-Pfeuty et al formation of pre-ribosomal particules (Shaw and Jordan, 1995; MeÂ leÁ se and Xue, 1995, for review). The maintenance of its integrity and function is thus essential for cell survival, all the more so in metabolically active cells which continually demand a large ribosomal production and a high level of protein synthesis. The nucleolus disaggregates in late prophase and reconstitutes in postmitotic cells when transcription is reinitiated (Gautier et al., 1992) . Nucleolin, one of the many nucleolar components, is a phosphoprotein which contains phosphorylation sites for p34 cdc2 and CKII, shuttles back and forth between the nucleolus and the cytoplasm (Nigg, 1992, for review) and is capable of binding SV40-type monopartite NLS motifs, suggesting its possible involvement in nuclear import (Xue and MeÂ leÁ se, 1994). A reduction in its level of expression stimulates transcription. Conceivably then, some of the eects generated by mitomycin C could be mediated by the alteration of particular nucleolar functions associated with the loss of nucleolin from the nucleolus (Ginisty et al., 1998, for review) . On the other hand, the high toxicity of the Cdk inhibitors in all phases of the cell cycle is not surprising in view of the catastrophic eect they exert on the nucleolar organization.
Lowering the concentration of the Cdk inhibitors by a factor 2.5 ± 3, which restores only 5 ± 10% of the full in vitro-measured activity of the Cdk complexes, is sucient to abolish almost all the phenotypes generated at the higher concentration. Under these conditions, the main phenotype generated is a reduction in the rate of progression through the G1 and S phases and, then, a slower overall rate of proliferation, one of the major eects previously ascribed to the two Cdk inhibitors (Schutte et al., 1997; Meijer, 1996 , for review). These observations would indicate that the targets of the roscovitine-sensitive kinase(s) involved in preserving nucleolar integrity and in preventing excessive nuclear stockpiling of wt p53 are very high anity substrates.
The role of inhibition of G1-speci®c cyclin-dependent kinases in the establishment of senescence A strong wt p53 nuclear induction and a nucleolar fragmentation occur as well when the untransformed IMR-90 cells are exposed to 25 mM roscovitine or 150 mM olomoucine. Yet the normal cells die much more slowly after developing features that are characteristic of the senescent state (not shown). This might result from the reduction in both RNA and protein synthesis imposed by the loss of nucleolar structure and function which would not arise as fast as in the tumor cells, due to the slower metabolism of normal cells. Before death, the normal cells appear arrested in a G1-like phase with high nuclear levels of p21
, which must restrain the activity of the G1 cyclin/Cdks, and thus reduce the rate of progression through G1 (El-Deiry et al., 1993; Harper et al., 1993 Harper et al., , 1995 Xiong et al., 1993a,b; Noda et al., 1994; Zhang et al., 1994) . To date, p21 has been shown to be a target of the p53 transcriptional activation function although it is also inducible via p53-independent pathways (Michieli et al., 1994) . It was not suspected that the inhibition of a G1 cyclin/ Cdk in itself could induce a nuclear accumulation of wt p53 and, hence, eventually lead to a further increase in the p21 mRNA and protein levels. This combination of events could create an ampli®cation loop that would culminate in a full inhibition of the G1 cyclin/Cdks, ending in a full inhibition of both RNA and protein synthesis and eventually cell death. Remarkably, p21 has been independently identi®ed as the product of the sdi1 gene, the expression of which rises 10 ± 20-fold upon the onset of the senescent phenotype and loss of cell proliferation (Noda et al., 1994) . Senescent cells also express enhanced levels of wt p53 and p16
INKa , a Cdk4-speci®c inhibitor, (Atadja et al., 1995; Alcorta et al., 1996; Rezniko et al., 1996; Hara et al., 1996; Xiong et al., 1993a; Serrano et al., 1993) . Conceivably, the establishment of senescence could result from the progressive loss of nucleolar functions normally maintained by the combined actions of G1 Cdks which, in the absence of appropriate stimuli, would gradually become inactivated by similar feedback mechanisms. It is at the very least intriguing that nucleolar fragmentation in yeast SGS1 mutants has been shown to be responsible for accelerated aging (Sinclair et al., 1997) . Since mutations in the yeast SGS1 and human related WRN genes exert similar eects, the authors suggested that a conserved mechanism built upon the nucleolus might underlie the process of aging in eukaryotes. Further studies, including electron microscopic observations, are required to investigate the possible changes in the nucleolar structure and function that could arise upon the onset of senescence which could be manipulated by the use of Cdk inhibitors.
Possible mechanism of regulation of nucleolar assembly and of wt p53 nuclear accumulation during the cell cycle
The kinase activities of the G1-speci®c Cdks are undetectable in early G1 phase. This can be explained for Cdk2 by the fact that its major G1-speci®c regulatory cyclin E subunit does not stably accumulate before mid-G1 (Ko et al., 1992; Dulic et al., 1992; Tsai et al., 1993; Ohtsubo et al., 1995) . The nucleoli of MCF-7 cells are not yet fully reformed 4 h after release from a nocodazole block, looking as small dots ( Figure 5 , row`C (NocR4 h') in which little nucleolin concentrates (not shown). If the nucleolar fragmentation induced by Cdk inhibitors results directly from an inactivation of the cyclin E/ Cdk2 complexes, the full reassembly of the nucleolus in early G1 might be expected reciprocally to depend on the reappearance of active cyclin E/Cdk2 complexes. The nucleoli also disorganize in late prophase, precisely when cyclin A becomes abruptly degraded and, hence, the active cyclin A/Cdk2 complexes, destroyed.
The facts that the highest nuclear concentrations of wt p53 are generally found in early G1 cells before the appearance of activated cyclin E/Cdk2 complexes and that continued inhibition by Cdk inhibitors of these complexes results in a nuclear stockpiling of wt p53 would suggest that the level of wt p53 nuclear accumulation during the cell cycle is negatively regulated by phosphorylation of speci®c cyclin E/ Cdk2 targets. wt p53 has been shown recently to carry a signal sequence similar to the nuclear export signal (NES) of the rev protein (Fischer et al., 1995) , which lies within its tetramerization domain (Stommel et al., 1999) . Therefore, the authors raised the possibility that the cell cycle-dependent localization of wt p53 could be regulated by its phosphorylation at S315 (which reduces the tetramer stability in vitro; Sakaguchi et al., 1997) by the Cdk1 and Cdk2 kinases after the restriction point. Its following association in the cytoplasm with its negative, NES-bearing Mdm2 regulator would then be required to facilitate its degradation via the ubiquitin-proteasome pathway (Roth et al., 1998) . Alternatively, phosphorylation could aect nuclear export itself rather than the export complex formation. If so, the Cdk inhibitors would be expected to alter the nucleocytoplasmic shuttling of other NES-bearing proteins as well. Interestingly, active Cdk2 molecules build up when wt p53 collects in the nucleus of cells treated with mitomycin C. This observation would favor the hypothesis that DNA damage and Cdk inhibitors stimulate a nuclear stockpiling of wt p53 via dierent pathways.
The possibility that the various eects induced by roscovitine and olomoucine are all attributable to an inhibition of the Cdk2 kinase is raised by the previous in vitro studies which have identi®ed this interphaseactive kinase, together with Cdk1 (the activity of which, however, does not emerge before G2) as the most selectively inhibited enzyme among 35 kinases tested (Vesely et al., 1994; De Azevedo et al., 1997) . Yet, given the estimation that mammalian cells express more than 2000 kinases, the possibility that other kinases might be involved in place of or in addition to Cdk2 should be kept in mind. Nonetheless, the observations that the in vivo potency of the two Cdk inhibitors parallels their in vitro ecacy and that the in vitro inactive isomer of olomoucine, iso-olomoucine, has no biological activity as well in vivo, is suggestive. Roscovitine and olomoucine also inhibit with a similar ecacy in vitro erk1 and erk2 (20 mM5IC 50 540 mM) which argues against the possibility that their in vivo action would be mediated via an inhibition of these kinases. It is worthy of note also that, at a partially inhibiting concentration, the Cdk inhibitors only reduce the rate of entry in S phase and of DNA replication, i.e. they produce eects similar to those reported earlier following either microinjection of anti-cyclin A (or anti-Cdk2) antibodies or transfection of a dominant negative Cdk2 and opposed to those resulting from an overexpression of cyclin E. Flavopiridol, a synthetic derivative of an alkaloid from the Indian plant Dysoxylum binectariferum (Sedlacek et al., 1996) , is also a very potent inhibitor of Cdks, although somewhat less selective than roscovitine since it inhibits with similar ecacy in vitro Cdk1, 2, 4 and 7 (Worland et al., 1993) . Because of its high toxicity on some cancer cells in vivo, it is a potentially promising anti-neoplastic agent already undergoing clinical trials. The IC 50 values of avopiridol and of roscovitine for Cdk2 are very close (0.4 vs 0.7 mM). It is then conceivable that the biological eects of¯avopiridol could also be mediated via an inhibition of Cdk2 and mimic those described here for roscovitine.
Materials and methods

Cell lines, cell culture and synchronization
The MCF-7 cell line was kindly provided by Evelyne May and the untransformed human IMR-90 ®broblasts, by Vincent Favaudon. Cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% (MCF-7) or 15% (IMR-90) fetal calf serum and antibiotics and maintained in a 10% CO 2 humidi®ed atmosphere at 378C.
To generate cell populations enriched in G1 cells, the IMR-90 cells were ®rst arrested at the G0/G1 checkpoint by lowering the serum concentration to 0.1% for three days and released in the cell cycle by transfer to 15% serum-containing medium. Generally, the ratio G2/M-and G0/G1-blocked cells reached 5 ± 8% and 88 ± 92%, respectively, and no more than 3% of the cells were in S phase before serum starvation release (Figure 6 ). Under the same synchronization conditions, the tumor-derived MCF-7 cells failed to exhibit a good G0/G1 arrest. Another synchronization approach was then used, which consists in ®rst blocking the cells around the G2/ M transition by incubation in the presence of 0.05 mg/ml nocodazole for 18 h and then releasing the cells from the mitotic block for 4 h before adding the drug. At that time, the ratio of G1 cells could vary between 70 and 80%, the remaining cells concentrating mostly in late G2 and M phases ( Figure 6 ). We chose to add the drugs at this time because we noted that a signi®cant re-entry in S phase started to occur after a longer time of release. An incubation with 4 mg/ml of aphidicolin for 16 h was also utilized to obtain populations of cells synchronized in early S phase. The chemical inhibitors of cyclin-dependent kinases, roscovitine, purvalanol B and olomoucine and the inactive isomer of olomoucine, isoolomoucine, have been generously provided by Laurent Meijer (CNRS, Rosco, France). The anti-mitotic drug, nocodazole, and DNA-alkylating agent, mitomycin C, were from Sigma (L'Isle d'Abeau Chesnes, France).
Immunochemical and staining reagent ± procedure for immuno¯uorescence
The mouse monoclonal antibodies NCL-DO7 which is highly speci®c for human wt p53 (Tebu, Le Perray-en-Yvelines, France) was used here to immunolocalize the protein and to reveal it on immunoblots. The rabbit polyclonal antinucleolin antibodies (Ghisolti-Nieto et al., 1996) were kindly provided by GeÂ rard Joseph (Philippe Bouvet laboratory, CNRS, Toulouse, France). The rabbit polyclonal anti-cyclin A antiserum, raised against the bacterially-produced and puri®ed human antigen was a generous gift from Tony Hunter (The Salk Institute, CA, USA). The rabbit polyclonal anti-cyclin E (C-19), sc-198, antiserum was from Tebu (Le Perray-en-Yvelines, France) and the anti-Cdk2 polyclonal, raised against residues 287 ± 298 of human Cdk2, from Euromedex (Souelweyersheim, France). The thymidine analog, 5-bromodeoxyuridine (BrdUrd) and 4,6-diamidino-2-phenylindole (DAPI, 1 mg/ml)¯uorescent dye (Sigma) were used respectively to identify cells undergoing DNA replication by¯ow cytometry and to counterstain DNA in immuno¯uorescence. The rat monoclonal anti-BrdUrd antibody (MAS 250b) was provided as a supernatant¯uid from a hybridoma cell line (Interchim, MontlucË on, France). Secondary antibodies were Fab fragments from goat IgGs raised against either mouse or rat or rabbit IgGs and conjugated either with¯uorescein isothiocyanate (FITC) or tetramethyl rhodamine isothiocyanate (TRITC) (Interchim).
Single-, double-or triple-¯uorescence cell labeling is generally performed after ®xation with 3% paraformaldehyde and subsequent permeabilization by treatment with 0.1% Triton X-100 at room temperature. Alternatively, cells are ®rst ®xed and permeabilized by treatment with methanol at 7208C for 6 min before application of the paraformaldehyde procedure when the paraformaldehyde procedure alone wt p53 nuclear induction by inhibition of Cdk2 kinase T David-Pfeuty et al is insucient to obtain a good immunolabeling of cells situated at the center of multicellular aggregates as occurs in MCF-7 cell populations. Immunolabeling with anti-cyclin A or with anti-cyclin B1 antibodies provides good markers of position in the cell cycle, because, in rat embryo ®broblasts (Girard et al., 1991) as well as in human normal and tumorderived cells Nouvian-Dooghe, 1996, 1997) , the ®rst appearance of nuclear cyclin A occurs just prior to the onset of S phase; the nuclear cyclin A concentration then steadily raises during progression through the S and G2 phases and reaches a peak in early prophase before cyclin A becomes abruptly degraded in metaphase and before anaphase. A cytoplasmic anti-cyclin B1 immunolabeling, on the other hand, does not start to emerge before the beginning of S phase; it then rises steeply in G2 phase and eventually relocates to the nucleus in early prophase . The DAPI staining allows to identify a particular mitotic stage starting from early prophase in which early chromosome condensation is re¯ected by the appearance of a characteristic punctate pattern. It is also peculiar in dying cells in which chromosomes aggregate in an erratic pattern. At last, phase contrast microscopy enables recognition of postmitotic cells (which, typically, exhibit a low degree of spreading and not yet fully expanded nuclei and remain connected through the midbody) as well as dying cells (which clearly display an aberrant morphology). Fluorescence microscopy has been performed with a Leitz microscope equipped with¯uorescein, rhodamine and DAPI ®lters using a 406 oil objective. Photographs were taken with Kodak TMax 400 ®lm.
Immunoblotting experiments
Preparation of cellular extracts for immunoblotting are made in lysis buer containing 10 mM Tris-HCl (pH 7.2), 150 mM NaCl, 0.5% sodium deoxycholate, 1% Triton X-100, 1 mM EDTA, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl¯uoride (PMSF), 10 mg/ml leupeptin, 100 kallikrein inactivator units of aprotinin and 1 mM Na 3 VO 4 . Protein separation is carried out by electrophoresis on SDS/ polyacrylamide gels (12.5% acrylamide/0.33% bisacrylamide) after boiling the samples for 3 min in 26SDS sample buer. The fractionated proteins are transferred to nitrocellulose at 600 mA for 3 h in cold room and, after blocking, the transfer membranes, are incubated in the presence of the appropriate antibody solution overnight at 48C. After several washes, they are exposed to horseradish peroxidaseconjugated antibody and detection of the immune complex is performed using the ECL Western blotting system (Amersham, France).
Flow cytometry
Prior to detection of BrdUrd-labeled cells as described by Wilson et al., (1985) , the cells are pulse-labeled with 30 mM BrdUrd for 15 min, washed in PBS, trypsinized and collected by centrifugation. After ®xation with 75% ethanol at 7208C for 10 min, the nuclei are isolated following treatment with 0.5% pepsin in 0.1 N HCl for 20 min and cellular DNA is partially denatured with 2 N HCl for 20 min at 378C. After several washes, they are incubated at RT successively with rat anti-BrdUrd antibodies (1 h) and with FITC-conjugated goat anti-rat IgG secondary antibody (0.5 h). They are then washed twice in PBS and stained with 25 mg/ml propidium iodide (PI) for 30 min at RT. Data are collected using a FACScan¯ow cytometer (Becton Dickinson & Co., San Jose, CA, USA). The green¯uorescence associated to BrdUrdlabeled cells is measured at 520 nm and the red one of PI at 4620 nm. The G1/S/G2-M ratio is determined from the bivariate BrdUrd versus DNA content plots by counting the number of dots in the appropriate area de®ned after performing control experiments in which the incubation with BrdUrd has been omitted. Counting is made on 10 000 cells.
In routine experiments, the rate of cell death as a function of the time of exposure to the various drugs was estimated by the Trypan blue exclusion assay. At the desired time, the medium containing¯oating cells is recollected and the adhering cells are detached by trypsinization and collected with the¯oating ones. Cell viability is estimated after adding an equivalent volume of a 0.125% Trypan blue solution to an aliquot of the whole suspended cells and counting under the microscope the proportion of unstained versus total cells deposited in a hemacytometer. Figure 1 displays plots presenting, for each time point, an average value of cell viability obtained from at least ®ve counts over dierent ®elds of *100 cells.
